OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
Key Highlights
- ➤Q3 revenue $21.6 million, down 17% year over year
- ➤Q3 adjusted EBITDA $6.3 million, up from $5.1 million
- ➤2026 revenue guidance reduced to $87-$93 million
- ➤2026 adjusted EBITDA guidance unchanged at $21-$25 million
- ➤OptimizeRx repaid $9.3 million debt principal, leaving $10.4 million outstanding
Expert Statements
Stephen L. Silvestro, CEO of OptimizeRx
“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model.”
Stephen L. Silvestro, CEO of OptimizeRx
“While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
Stephen L. Silvestro, CEO of OptimizeRx
“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”
Stephen L. Silvestro, CEO of OptimizeRx
“We are seeing expanding opportunities within key accounts, renewed spending in the fourth quarter from a previously significant customer, and indications of pent-up demand as customers execute against their marketing budgets for the 2027 RFP season.”
Stephen L. Silvestro, CEO of OptimizeRx
“We believe these developments, along with our continued focus on strengthening our commercial leadership and broadening our product capabilities, position us to capture additional demand and support future growth.”
Stephen L. Silvestro, CEO of OptimizeRx
“More importantly, we believe OptimizeRx is uniquely positioned for the next evolution of healthcare marketing through three fundamental competitive advantages: our proven and increasingly scalable artificial intelligence (AI)-enabled platform, our proprietary healthcare data and solutions that are difficult to replicate or disintermediate, and our deeply integrated EHR network with substantial reach and meaningful barriers to entry.”
Stephen L. Silvestro, CEO of OptimizeRx
“Our Dynamic Audience Activation Platform and expanding AI-enabled audience intelligence capabilities demonstrate the value of these investments, while our partnerships with DeepIntent, The Trade Desk, and PulsePoint are broadening programmatic access to our proprietary network.”
Stephen L. Silvestro, CEO of OptimizeRx
“Together, these initiatives create opportunities to increase network utilization, expand customer reach, and capture a greater share of pharmaceutical marketing budgets.”
Stephen L. Silvestro, CEO of OptimizeRx
“We believe the progress we've made throughout 2026 has established a stronger foundation for sustainable, profitable growth and long-term shareholder value creation.”
* Q3 revenue totals $21.6 million * Q3 net income and adjusted EBITDA of $1.2 million and $6.3 million * 2026 revenue guidance updated to $87-$93 million; adjusted EBITDA guidance unchanged at $21-$25 million * Repaid $9.3 million in debt principal since June 30, 2026, reducing current outstanding principal to $10.4 million WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.
Financial Highlights * Revenue decreased 17% to $21.6 million in Q3 2026, compared to $26.1 million in Q3 2025. * GAAP net income of $1.2 million or $0.06 per basic and diluted share in Q3 2026, compared to GAAP net income of $0.8 million, or $0.04 per basic and diluted share, in Q3 2025. * Non-GAAP net income of $3.8 million, or $0.20 per diluted share in Q3 2026, compared to Non-GAAP net income of $3.1 million or $0.16 per diluted share, in Q3 2025. (See *Non-GAAP Measures below) * Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million in Q3 2025. (See *Non-GAAP Measures below) * Operating cash flow was $12.9 million for the nine months ended September 30, 2026 and the Company had cash and cash equivalents of $22.3 million as of September 30, 2026 compared to $23.4 million as of December 31, 2025. Stephen L. Silvestro, OptimizeRx CEO commented, “Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.
Get started
Create a free account to read the full story.